We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $931M
1-Year Est. Return 41.63%
This Fund
S&P 500
This Quarter Est. Return
-13.01%
1 Year Est. Return
+41.63%
3 Year Est. Return
+181.18%
5 Year Est. Return
+113.34%
10 Year Est. Return
+1,823.73%
AUM
$2.79B
AUM Growth
-$283M
Cap. Flow
-$54.4M
Cap. Flow %
-1.95%
Top 10 Hldgs %
67.96%
Holding
104
New
24
Increased
12
Reduced
21
Closed
21

Top Buys

Rank Stock Value
1
PCYC
PHARMACYCLICS INC
PCYC
+$20M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$10.2M
3
GM icon
General Motors
GM
+$9.45M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$7.46M
5
CCI icon
Crown Castle
CCI
+$7.4M

Top Sells

Rank Stock Value
1
AUXL
AUXILIUM PHARAMCEUTICALS INC
AUXL
+$21.4M
2
ACOR
Acorda Therapeutics
ACOR
+$12.8M
3
F icon
Ford
F
+$10.1M
4
TEX icon
Terex
TEX
+$9.24M
5
UAL icon
United Airlines
UAL
+$8.76M

Sector Composition

Rank Sector Weight
1 Miscellaneous 41.56%
2 Consumer Discretionary 34.56%
3 Healthcare 22.36%
4 Financials 0.62%
5 Real Estate 0.57%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NG icon
76
NovaGold Resources
NG
$3.17B
$2.54M 0.09%
1,000,000
– –
IRWD icon
77
Ironwood Pharmaceuticals
IRWD
$689M
$2.52M 0.09%
258,954
– –
AMBI
78
DELISTED
Ambit Biosciences Corp
AMBI
$2.41M 0.09%
+250,000
New +$3.34M
AMRN
79
CALL
Amarin Corp
AMRN
$291M
$1.97M 0.07%
50,000
– –
VNDA icon
80
Vanda Pharmaceuticals
VNDA
$311M
$1.86M 0.07%
+150,000
New +$1.51M
CCXI
81
DELISTED
ChemoCentryx, Inc.
CCXI
$1.59M 0.06%
275,000
– –
VNDA icon
82
CALL
Vanda Pharmaceuticals
VNDA
$311M
$1.24M 0.04%
+100,000
New +$1M
AGEN
83
Agenus
AGEN
$312M
$1.08M 0.04%
20,896
– –
AIG icon
84
American International
AIG
$39.4B
– –
-100,000
Closed -$4.98M
CPRI icon
85
Capri Holdings
CPRI
$1.61B
– –
-100,000
Closed -$7.45M
DG icon
86
Dollar General
DG
$27.5B
– –
-100,000
Closed -$5.65M
EWW icon
87
CALL
iShares MSCI Mexico ETF
EWW
$1.73B
– –
-150,000
Closed -$9.58M
F icon
88
Ford
F
$55.3B
– –
-600,000
Closed -$10.1M
JPM icon
89
CALL
JPMorgan Chase
JPM
$931B
– –
-700,000
Closed -$35.9M
LAB icon
90
Standard BioTools
LAB
$271M
– –
-168,706
Closed -$3.7M
LEN icon
91
Lennar Class A
LEN
$19.2B
– –
-52,528
Closed -$1.77M
MS icon
92
Morgan Stanley
MS
$324B
– –
-100,000
Closed -$2.69M
PHM icon
93
CALL
Pultegroup
PHM
$22.7B
– –
-250,000
Closed -$4.13M
QCOM icon
94
Qualcomm
QCOM
$192B
– –
-50,000
Closed -$3.53M
TEX icon
95
Terex
TEX
$6.95B
– –
-275,000
Closed -$9.24M
UAL icon
96
United Airlines
UAL
$35.4B
– –
-250,000
Closed -$8.76M
ALBO
97
DELISTED
Albireo Pharma Inc
ALBO
– –
-9,691
Closed -$916K
MTOR
98
CALL
DELISTED
MERITOR, Inc.
MTOR
– –
-250,000
Closed -$1.97M
SMT
99
DELISTED
SMART TECHNOLOGIES INC COM NEW
SMT
– –
-55,000
Closed -$1.55M
SUNE
100
DELISTED
SUNEDISON, INC COM
SUNE
– –
-250,000
Closed -$1.99M
1 2 3
4
5

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $931M AUM 47.97% 1-Year Est. Return
ACM
Ashe Capital Management Englewood Cliffs, New Jersey $931M AUM 4.95% 1-Year Est. Return
SAM
Sycomore Asset Management Paris, France $932M AUM 51.25% 1-Year Est. Return
NS
Night Squared New York $930M AUM 56.46% 1-Year Est. Return
PA
Planning Alternatives Birmingham, Michigan $933M AUM 28.32% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $933M AUM 56.2% 1-Year Est. Return
CICI
Capital Investment Counsel Inc Raleigh, North Carolina $929M AUM 53.07% 1-Year Est. Return
CAM
Claret Asset Management Montreal, Quebec, Canada $928M AUM 25.4% 1-Year Est. Return

Artal Group's Q4 2013 Portfolio in Review

As of Q4 2013, Artal Group held 104 positions worth $2.79B, down 9.2% from $3.07B the previous quarter. Its ten largest holdings account for 68% of the portfolio.

Artal Group's Q4 2013 filing shows 24 new, 12 increased, 21 reduced and 21 closed positions. Its largest new stake was PHARMACYCLICS INC: 165,000 shares worth $17.5M. The largest sale was AUXILIUM PHARAMCEUTICALS INC, an estimated $21.4M.

By sector, the portfolio is most concentrated in Miscellaneous at 42% of assets, up from 37% a quarter earlier, followed by Consumer Discretionary and Healthcare.

  • Artal Group's largest Q4 2013 buy was PHARMACYCLICS INC: 165,000 shares worth $17.5M.
  • Artal Group added most to BioMarin Pharmaceuticals in Q4 2013, an estimated $10.2M increase.
  • Artal Group's biggest Q4 2013 reduction was AUXILIUM PHARAMCEUTICALS INC, cutting an estimated $21.4M.
  • Artal Group fully exited Ford in Q4 2013, selling an estimated $10.1M.
  • Artal Group's ten largest holdings make up 68% of its $2.79B portfolio in Q4 2013.
  • Artal Group opened 24 new positions and closed 21 in Q4 2013.
  • Artal Group's portfolio value fell 9.2% quarter-over-quarter to $2.79B.

Based on Artal Group's 13F filing for Q4 2013, filed 14 Feb 2014.